lauric acid has been researched along with Prostatic Hyperplasia in 3 studies
dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of benign prostatic hyperplasia can be accomplished by the use of different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor." | 7.79 | Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. ( Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F, 2013) |
| "Lauric acid/myristic acid treatment showed significant inhibition of prostate enlargement and protection of histoarchitecture of prostate when compared with positive control group." | 5.36 | Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. ( Patil, AA; Veeresh Babu, SV; Veeresh, B; Warke, YB, 2010) |
| "The treatment of benign prostatic hyperplasia can be accomplished by the use of different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor." | 3.79 | Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. ( Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F, 2013) |
| "Lauric acid/myristic acid treatment showed significant inhibition of prostate enlargement and protection of histoarchitecture of prostate when compared with positive control group." | 1.36 | Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. ( Patil, AA; Veeresh Babu, SV; Veeresh, B; Warke, YB, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pupe, CG | 1 |
| Do Carmo, FA | 1 |
| De Sousa, VP | 1 |
| Lopes, M | 1 |
| Abrahim-Vieira, B | 1 |
| Ribeiro, AJ | 1 |
| Veiga, F | 1 |
| Rodrigues, CR | 1 |
| Padula, C | 1 |
| Santi, P | 1 |
| Cabral, LM | 1 |
| Veeresh Babu, SV | 1 |
| Veeresh, B | 1 |
| Patil, AA | 1 |
| Warke, YB | 1 |
| Arruzazabala, ML | 1 |
| Pérez, Y | 1 |
| Ravelo, Y | 1 |
| Molina, V | 1 |
| Carbajal, D | 1 |
| Mas, R | 1 |
| Rodríguez, E | 1 |
3 other studies available for lauric acid and Prostatic Hyperplasia
| Article | Year |
|---|---|
Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; An | 2013 |
Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats.
Topics: Administration, Oral; Animals; Body Weight; Lauric Acids; Male; Myristic Acid; Organ Size; Prostate; | 2010 |
Effect of oleic, lauric and myristic acids on phenylephrine-induced contractions of isolated rat vas deferens.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Arecaceae; In Vitro Techniques; Lauric Acids; Male | 2011 |